In March 2023, we shared topline results from our Essential1 Phase 2 study for Essential Tremor (ET). Results show potential for ulixacaltamide (previously PRAX-944) to transform the treatment of essential tremor. At Praxis, we understand that ET is more than tremor and that it can have a deep and far-reaching impact on the lives of people living with the condition as well as their care partners and communities.

See results of the Essential1 Study below

We use cookies to improve your experience and to help us understand how you use our site. Please refer to our cookie notice and privacy statement for more information regarding cookies and other third-party tracking that may be enabled.

For more information on Praxis, including our privacy policy, visit us at If you have any questions, please email us at

© 2023 Praxis Precision Medicines, Inc.

Twitter icon
YouTube icon
LinkedIn icon
Website icon
Facebook icon
Intuit Mailchimp logo